StreetInsider.com News Articles

Mirum Pharmaceuticals (MIRM) Reiterated at Market Outperform by Citizens

Thu, 27 Aug 2026 04:29:49 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $137.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).

The analyst commented, "The interim AZURE-1 data confirmed our view that brelovitug is a differentiated candidate in the HDV landscape and also substantially derisked the pivotal AZURE-1 and AZURE-4 readouts. We like that the week 24 responses were competitive, with efficacy observed for the approved and late-stage candidates at longer time points, and importantly, the safety profile looked clean. We also know from prior brelovitug data (and other HDV candidates) that response rates will continue to improve over time, so while this 24-week

H.C. Wainwright Reiterates Buy Rating on Mirum Pharmaceuticals (MIRM)

Thu, 20 Aug 2026 06:53:04 -0400

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $140.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).

The analyst commented: "On August 19, 2026, FDA approved Regeneron Pharmaceuticals’ garetosmab (Pasatru), an intravenous (IV) anti-Activin A monoclonal antibody, to reduce the formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Regeneron plans to initiate OPTIMA 2, a Phase 3 study in adolescents and children, later this year. The treatment is dosed at 10 mg/kg IV over 60 minutes once monthly, reducible to 3 mg/kg if not well tolerated, and the label permits administration

Form 4 Mirum Pharmaceuticals, For: Aug 18 Filed by: Howe Jolanda

Wed, 19 Aug 2026 18:19:00 -0400

si-local-file:///var/storage/secattach/20260819/26951390.html

Form 4 Mirum Pharmaceuticals, For: Aug 18 Filed by: Howe Jolanda

Wed, 19 Aug 2026 18:19:00 -0400

si-local-file:///var/storage/secattach/20260819/26951390.html

Form 144 Mirum Pharmaceuticals, Filed by: Howe Jolanda

Tue, 18 Aug 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260818/26945531.html

Form 144 Mirum Pharmaceuticals, Filed by: Howe Jolanda

Tue, 18 Aug 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260818/26945531.html

Form SCHEDULE 13G/A Mirum Pharmaceuticals, Filed by: Janus Henderson Group Ltd.

Thu, 13 Aug 2026 12:48:00 -0400

si-local-file:///var/storage/secattach/20260813/26919268.html

Form SCHEDULE 13G/A Mirum Pharmaceuticals, Filed by: Janus Henderson Group Ltd.

Thu, 13 Aug 2026 12:48:00 -0400

si-local-file:///var/storage/secattach/20260813/26919268.html

Form 4 Mirum Pharmaceuticals, For: Aug 11 Filed by: BJERKHOLT ERIC

Wed, 12 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260812/26914273.html

Form 4 Mirum Pharmaceuticals, For: Aug 11 Filed by: BJERKHOLT ERIC

Wed, 12 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260812/26914273.html

Form 4 Mirum Pharmaceuticals, For: Aug 10 Filed by: Peetz Christopher

Tue, 11 Aug 2026 17:42:00 -0400

si-local-file:///var/storage/secattach/20260811/26907277.html

Form 4 Mirum Pharmaceuticals, For: Aug 10 Filed by: Peetz Christopher

Tue, 11 Aug 2026 17:42:00 -0400

si-local-file:///var/storage/secattach/20260811/26907277.html

Form 144 Mirum Pharmaceuticals, Filed by: BJERKHOLT ERIC

Tue, 11 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260811/26905835.html

Form 144 Mirum Pharmaceuticals, Filed by: BJERKHOLT ERIC

Tue, 11 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260811/26905835.html

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 11 Aug 2026 16:01:00 -0400

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on August 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 26,050 shares of common stock and 34,590 restricted stock units (“RSUs”) to 19 new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price of $98.70 per share, which

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 11 Aug 2026 16:01:00 -0400

Each stock option has an exercise price of $98.70 per share, which

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 11 Aug 2026 16:01:00 -0400

Each stock option has an exercise price of $98.70 per share, which

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 11 Aug 2026 16:01:00 -0400

Each stock option has an exercise price of $98.70 per share, which

Form 144 Mirum Pharmaceuticals, Filed by: Peetz Christopher

Mon, 10 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260810/26898203.html

Form 144 Mirum Pharmaceuticals, Filed by: Peetz Christopher

Mon, 10 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260810/26898203.html

Form SCHEDULE 13G Mirum Pharmaceuticals, Filed by: FMR LLC

Thu, 06 Aug 2026 10:36:00 -0400

si-local-file:///var/storage/secattach/20260806/26881319.html

Form SCHEDULE 13G Mirum Pharmaceuticals, Filed by: FMR LLC

Thu, 06 Aug 2026 10:36:00 -0400

si-local-file:///var/storage/secattach/20260806/26881319.html

Mirum Pharmaceuticals (MIRM) PT Lowered to $137 at Morgan Stanley

Thu, 06 Aug 2026 08:52:22 -0400

Morgan Stanley analyst Michael E Ulz lowered the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $137.00 (from $150.00) while maintaining a Overweight rating.

Mirum Pharmaceuticals (MIRM) PT Lowered to $123 at Baird

Thu, 06 Aug 2026 08:30:51 -0400

Baird analyst Brian Skorney lowered the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $123.00 (from $129.00) while maintaining a Outperform rating.

Mirum Pharmaceuticals (MIRM) PT Lowered to $140 at TD Cowen

Thu, 06 Aug 2026 08:08:06 -0400

TD Cowen analyst Joseph Thome lowered the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $140.00 (from $145.00) while maintaining a Buy rating.